Correction: Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors

Clin Cancer Res. 2024 Sep 3;30(17):3957. doi: 10.1158/1078-0432.CCR-24-2131.
No abstract available

Publication types

  • Published Erratum